Clinical studies of the original drug goflikicept, developed by the R-Pharm group of companies, have commenced at the First Moscow State Medical University. The drug is intended for the treatment of adult patients with familial Mediterranean fever.
Goflikicept is a groundbreaking protein medication that neutralizes the cytokine interleukin-1β (IL-1), a pivotal factor in the progression of Mediterranean fever.
Familial Mediterranean fever (FMF) is an autoinflammatory genetic disorder that mainly affects people of Mediterranean origin. FMF is characterized by recurrent episodes of fever and serositis (chest, abdomen, joints), leading to painful attacks early during childhood. Amyloidosis is the most fatal complication of FMF
